Medication.

In this prospective multicentre, open-label, 6-month study (Paliperidone Palmitate Flexible Dosing in Schizophrenia [PALMFlexS]), tolerability, safety and treatment response with paliperidone palmitate (PP) were explored in patients with acute symptoms of schizophrenia following switching from previously unsuccessful treatment with oral antipsychotics. This pragmatic study was conducted in a large, more representative sample of the general schizophrenia population compared to randomized controlled pivotal trials, to specifically mimic real-world clinical situations.

http://www-scopus-com.lcproxy.shu.ac.uk/record/display.url?eid=2-s2.0-84918791715&origin=resultslist&sort=plf-f&src=s&st1=schizophrenia+AND+medication&sid=2F45B0988E510264E89284138C608CAA.Vdktg6RVtMfaQJ4pNTCQ%3a20&sot=b&sdt=b&sl=43&s=TITLE-ABS-KEY%28schizophrenia+AND+medication%29&relpos=0&relpos=0&citeCnt=0&searchTerm=TITLE-ABS-KEY%28schizophrenia+AND+medication%29

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>